Express Scripts Includes Innovative Cholesterol-Lowering Drugs on National Preferred Formulary
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Express Scripts (ESRX) Includes Praluent and Repatha on National Preferred Formulary
October 6, 2015 5:06 PM EDTTo ensure clinically appropriate, cost-effective use of two new cholesterol-lowering drugs, Express Scripts (NASDAQ: ESRX) today announced it will include both Praluent and Repatha on its National Preferred Formulary, the nation's largest formulary covering approximately 25 million Americans.
"As always, we make sure our patients access the right medications at the best possible price with the greatest level of care," said Dr. Steve Miller, Senior Vice President and Chief Medical Officer of Express Scripts. "Since these new medications were approved a few months ago, our pharmacy experts have worked with medical professionals and... More
